EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.…
EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
EyePoint (NASDAQ: EYPT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 214 employees.
The shares were at 0.2342 USD on 20 November 2026, down 97.9% over 52 weeks. Its 52-week range is 0.2277 USD to 19.11 USD: the price is 98.8% below the high and 2.9% above the low.
Its market capitalisation is 26.65M USD.
EyePoint reports return on equity of -75.8% and revenue down 21.7% year over year.
It holds more cash than debt, a net cash position of 96.46M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 10 March 2027.